CONTRIBUTORS TO THIS PROFILE
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.
Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Funding Rounds (3) - $61.9MUpdate
OrbiMed is a healthcare-dedicated investment...
Forbion Capital Partners is a Netherlands-based...
Crédit Agricole Private Equity supports...
LSP BioVentures is a venture capital fund...
Venture capital Firm
PMV is an independent investment company. It...
Private Equity Bank
Dr Molewaterplein 50